Analysts Set Exact Sciences Corporation (NASDAQ:EXAS) Target Price at $92.13

The average 12-month price target among analysts covering the stock is $92.13.

Mar. 12, 2026 at 6:08am

Got story updates? Submit your updates here. ›

Exact Sciences Corporation (NASDAQ:EXAS) has received an average rating of 'Reduce' from the twenty-two analysts covering the company, according to MarketBeat Ratings. One analyst has rated the stock with a sell recommendation and twenty-one have assigned a hold recommendation. The average 12-month price target among analysts who have updated their coverage on the stock in the last year is $92.13.

Why it matters

Analyst price targets and ratings can provide insights into the market's sentiment and expectations for a company's stock performance. The relatively low average price target and 'Reduce' rating from analysts covering Exact Sciences suggest they are not particularly bullish on the stock's near-term prospects.

The details

The analysts' average price target of $92.13 represents a modest premium to Exact Sciences' current trading price, but the predominance of 'hold' recommendations indicates analysts see limited upside in the stock. Several analysts have recently downgraded Exact Sciences, cutting their ratings from 'buy' or 'overweight' to 'neutral' or 'hold'.

  • Exact Sciences last reported quarterly earnings on February 13, 2026.

The players

Exact Sciences Corporation

A molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company's flagship product is the Cologuard noninvasive, stool-based DNA screening test for colorectal cancer.

MarketBeat Ratings

A research firm that tracks and reports on analyst ratings and price targets for publicly traded companies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The relatively muted analyst sentiment on Exact Sciences' stock suggests the market may be skeptical about the company's near-term growth prospects, despite its innovative cancer screening technology. Investors will likely be watching closely to see if Exact Sciences can exceed expectations and change the minds of the analysts covering the stock.